J. Russell Teagarden

1.7k total citations
44 papers, 1.0k citations indexed

About

J. Russell Teagarden is a scholar working on Economics and Econometrics, Geriatrics and Gerontology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, J. Russell Teagarden has authored 44 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Economics and Econometrics, 15 papers in Geriatrics and Gerontology and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in J. Russell Teagarden's work include Pharmaceutical Economics and Policy (18 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Pharmaceutical Practices and Patient Outcomes (15 papers). J. Russell Teagarden is often cited by papers focused on Pharmaceutical Economics and Policy (18 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Pharmaceutical Practices and Patient Outcomes (15 papers). J. Russell Teagarden collaborates with scholars based in United States, United Kingdom and Australia. J. Russell Teagarden's co-authors include Robert S. Epstein, Ronald E. Aubert, Jianying Yao, Ashish K. Jha, Fang Xia, Robert R. Verbrugge, Thomas P. Moyer, Dennis J. O’Kane, Brian F. Gage and Todd C. Skaar and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

J. Russell Teagarden

39 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Russell Teagarden United States 15 309 258 204 165 129 44 1.0k
RJ Glynn United States 14 355 1.1× 527 2.0× 228 1.1× 240 1.5× 139 1.1× 20 1.4k
Michele M. Spence United States 13 265 0.9× 149 0.6× 181 0.9× 151 0.9× 78 0.6× 24 1.2k
Martina Teichert Netherlands 19 272 0.9× 252 1.0× 148 0.7× 71 0.4× 86 0.7× 81 1.1k
Nancy L. Shapiro United States 19 364 1.2× 405 1.6× 75 0.4× 158 1.0× 36 0.3× 51 1.1k
Gloria R. Grice United States 16 216 0.7× 864 3.3× 165 0.8× 339 2.1× 96 0.7× 31 1.3k
Arja Helin‐Salmivaara Finland 19 285 0.9× 121 0.5× 375 1.8× 98 0.6× 188 1.5× 37 1.4k
Matthijs L. Becker Netherlands 21 288 0.9× 256 1.0× 97 0.5× 394 2.4× 57 0.4× 62 1.8k
Federica Nicotra Italy 16 487 1.6× 97 0.4× 163 0.8× 155 0.9× 189 1.5× 21 1.5k
Samuel G. Johnson United States 18 223 0.7× 532 2.1× 157 0.8× 92 0.6× 29 0.2× 36 1.3k
Michael B. Bottorff United States 18 574 1.9× 158 0.6× 151 0.7× 150 0.9× 67 0.5× 67 1.4k

Countries citing papers authored by J. Russell Teagarden

Since Specialization
Citations

This map shows the geographic impact of J. Russell Teagarden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Russell Teagarden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Russell Teagarden more than expected).

Fields of papers citing papers by J. Russell Teagarden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Russell Teagarden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Russell Teagarden. The network helps show where J. Russell Teagarden may publish in the future.

Co-authorship network of co-authors of J. Russell Teagarden

This figure shows the co-authorship network connecting the top 25 collaborators of J. Russell Teagarden. A scholar is included among the top collaborators of J. Russell Teagarden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Russell Teagarden. J. Russell Teagarden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Teagarden, J. Russell. (2020). From Atoms, Molecules, and Numbers to Literature, Art, and Performance. American Journal of Pharmaceutical Education. 84(4). 7636–7636. 1 indexed citations
2.
Yang, Mo, et al.. (2019). Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?. Value in Health. 22(6). 642–647. 29 indexed citations
3.
Epstein, Robert S., J. Russell Teagarden, Ali Çimen, Mark Sostek, & Tehseen Salimi. (2017). When People with Opioid-Induced Constipation Speak: A Patient Survey. Advances in Therapy. 34(3). 725–731. 14 indexed citations
4.
Teagarden, J. Russell, et al.. (2014). An Early Examination of Access to Select Orphan Drugs Treating Rare Diseases in Health Insurance Exchange Plans. Journal of Managed Care Pharmacy. 20(10). 997–1004. 10 indexed citations
5.
Teagarden, J. Russell. (2014). Managing Heterogeneity in Prescription Drug Coverage Policies. Journal of Managed Care Pharmacy. 20(6). 564–565. 1 indexed citations
6.
Wanner, Adam, Stephen C. Groft, J. Russell Teagarden, et al.. (2014). Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 2(2). 177–190. 6 indexed citations
7.
Teagarden, J. Russell, et al.. (2014). Access and availability of orphan drugs in the United States: advances or cruel hoaxes?. Expert Opinion on Orphan Drugs. 2(11). 1147–1150. 5 indexed citations
8.
Teagarden, J. Russell. (2013). Well Connected: Pharmacy Education and the Humanities. Journal of Medical Humanities. 34(4). 477–480. 7 indexed citations
9.
Teagarden, J. Russell, et al.. (2012). Influence of Pharmacy Benefit Practices on Off-Label Dispensing of Drugs in the United States. Clinical Pharmacology & Therapeutics. 91(5). 943–945. 6 indexed citations
10.
11.
Epstein, Robert S. & J. Russell Teagarden. (2010). Comparative Effectiveness Research and Personalized Medicine. PharmacoEconomics. 28(10). 905–913. 29 indexed citations
12.
Epstein, Robert S., Thomas P. Moyer, Ronald E. Aubert, et al.. (2010). Warfarin Genotyping Reduces Hospitalization Rates. Journal of the American College of Cardiology. 55(25). 2804–2812. 224 indexed citations
13.
Teagarden, J. Russell. (2006). Medication Therapy Management and the Medicare Prescription Drug Benefit. Hospital Pharmacy. 41(1). 88–90.
14.
Teagarden, J. Russell, et al.. (2005). Dispensing Error Rate in a Highly Automated Mail‐Service Pharmacy Practice. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(11). 1629–1635. 33 indexed citations
15.
Sabin, James E., Norman Daniels, & J. Russell Teagarden. (2004). The Perfect Storm. Psychiatric Annals. 34(2). 125–132. 1 indexed citations
16.
Teagarden, J. Russell. (2004). Perspectives on Prescription Drug Benefit Formularies. Hospital Pharmacy. 39(11). 1102–1105. 2 indexed citations
17.
Teagarden, J. Russell. (2003). Pharmacists, Ethics, and Pharmacy Benefits. American Journal of Pharmaceutical Education. 67(2). 51–51.
18.
Teagarden, J. Russell. (1998). The Effect of Pharmacy Benefit Manager Clinical Programs and Services on Access to Prescription Drug Benefit Coverage. Drug Information Journal. 32(2). 373–377. 7 indexed citations
19.
Teagarden, J. Russell. (1989). Meta‐Analysis: Whither Narrative Review?. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 9(5). 274–284. 34 indexed citations
20.
Kaplan, Kerry, et al.. (1985). Association of methemoglobinemia and intravenous nitroglycerin administration. The American Journal of Cardiology. 55(1). 181–183. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by RJ Glynn Breakdown of academic impact, for papers by Michele M. Spence Breakdown of academic impact, for papers by Martina Teichert Breakdown of academic impact, for papers by Nancy L. Shapiro Breakdown of academic impact, for papers by Gloria R. Grice Breakdown of academic impact, for papers by Arja Helin‐Salmivaara Breakdown of academic impact, for papers by Matthijs L. Becker Breakdown of academic impact, for papers by Federica Nicotra Breakdown of academic impact, for papers by Samuel G. Johnson Breakdown of academic impact, for papers by Michael B. Bottorff
Rankless by CCL
2026